Bank of New York Mellon’s Outlook Therapeutics OTLK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$29.7K Buy
+18,664
New +$11.6K ﹤0.01% 4255
2025
Q2
Sell
-27,324
Closed -$33.3K 4233
2025
Q1
$33.3K Sell
27,324
-2,440
-8% -$4.28K ﹤0.01% 4073
2024
Q4
$56.3K Buy
29,764
+9,211
+45% +$37.9K ﹤0.01% 4070
2024
Q3
$110K Buy
20,553
+193
+0.9% +$1.41K ﹤0.01% 4001
2024
Q2
$150K Buy
20,360
+377
+2% +$3.03K ﹤0.01% 3988
2024
Q1
$239K Sell
19,983
-1,745
-8% -$14.1K ﹤0.01% 3879
2023
Q4
$171K Hold
21,728
﹤0.01% 3993
2023
Q3
$96K Sell
21,728
-1,963
-8% -$43.4K ﹤0.01% 4088
2023
Q2
$824K Buy
23,691
+2,612
+12% +$71.2K ﹤0.01% 3322
2023
Q1
$460K Buy
21,079
+3,199
+18% +$71.6K ﹤0.01% 3534
2022
Q4
$386K Sell
17,880
-15
-0.1% -$326 ﹤0.01% 3682
2022
Q3
$437K Buy
17,895
+1,298
+8% +$30.2K ﹤0.01% 3641
2022
Q2
$339K Sell
16,597
-24
-0.1% -$690 ﹤0.01% 3819
2022
Q1
$592K Buy
16,621
+2,081
+14% +$65K ﹤0.01% 3612
2021
Q4
$395K Buy
14,540
+246
+2% +$8.78K ﹤0.01% 3945
2021
Q3
$621K Buy
14,294
+2,670
+23% +$129K ﹤0.01% 3676
2021
Q2
$578K Buy
11,624
+6,865
+144% +$318K ﹤0.01% 3703
2021
Q1
$214K Sell
4,759
-417
-8% -$16K ﹤0.01% 4031
2020
Q4
$135K Buy
5,176
+2,633
+104% +$55K ﹤0.01% 4045
2020
Q3
$37K Hold
2,543
﹤0.01% 4050
2020
Q2
$66K Hold
2,543
﹤0.01% 3944
2020
Q1
$31K Buy
+2,543
New +$42.2K ﹤0.01% 4019

Other funds holding OTLK

Bank of New York Mellon's OTLK Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Outlook Therapeutics (OTLK) in Q2 2026: 18,664 shares worth $29.7K. The stake represents ﹤0.01% of the portfolio and ranks #4255 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in OTLK as recently as Q1 2025.

Bank of New York Mellon first reported a position in OTLK in Q1 2020 and has held it in 22 quarters since. The position peaked at $824K in Q2 2023. 31 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

  • Bank of New York Mellon held 18,664 shares of Outlook Therapeutics worth $29.7K as of Q2 2026.
  • Outlook Therapeutics was a new Bank of New York Mellon position in Q2 2026.
  • Outlook Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4255 holding.
  • Bank of New York Mellon first reported a position in Outlook Therapeutics in Q1 2020 and has held it in 22 quarters since.
  • Bank of New York Mellon's Outlook Therapeutics position peaked at $824K in Q2 2023.
  • 31 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.